Skip to content
KJS Consulting LLC
Strategic Communications Solutions
  • Home
  • About KJS
  • Services
  • Blog
  • Contact KJS
  • Portfolio

Month: August 2017

NFL All-Pro Richard Sherman joins Oxeia board as it readies phase 2 concussion drug research

August 28, 2017 kjsllc Leave a comment

Early stage concussion drug developer Oxeia Biopharmaceuticals notched an outside-the-lab win last week, signing NFL star cornerback Richard Sherman to its…

Continue Reading →

Posted in: Uncategorized

Surprise: A short list of TV-ad drug risks is easier to recall, FDA study finds

August 16, 2017 kjsllc Leave a comment

Ready to say goodbye to the laundry list of risks in pharma TV ads? Don’t hold your breath, but one…

Continue Reading →

Posted in: Uncategorized

Aka-what? Fanapt maker Vanda puts antipsychotic side effect front and center in TV awareness ads

August 14, 2017 kjsllc Leave a comment

Vanda Pharmaceuticals recently rolled out a national TV campaign about akathisia, a little-known side effect of some schizophrenia medications, echoing…

Continue Reading →

Posted in: Uncategorized

Spoiler alert: IBD superheroes prevail as Takeda wraps its Marvel Comics project

August 7, 2017 kjsllc Leave a comment

Takeda closed the book—graphic novel, that is—on its inflammatory bowel disease awareness partnership with Marvel. The Unbeatables superhero team triumphs…

Continue Reading →

Posted in: Uncategorized

Recent Posts

  • No pharma Grand Prix—again—at Cannes Lions Health, but record number of awards for drugmakers
  • One Show renews health and pharma ad awards, citing better creative in the industry
  • 2018’s best-sellers? AbbVie’s Humira, obviously, but newcomers are on their way

Recent Comments

    Archives

    • June 2018
    • January 2018
    • December 2017
    • September 2017
    • August 2017
    • July 2017
    • June 2017
    • May 2017
    • April 2017

    Kara J. Stancell

    • Email
      kstancell@kjsconsultingllc.com
    • Phone
      (480) 442-9405
    Copyright © 2023 KJS Consulting LLC